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Abstract
Based on epidemiological data we can assume that at least some malignant melanoma (MM) and breast cancer
cases can be caused by the same genetic factors. CDKN2A, which encodes the p16 protein, a cyclin-dependent
kinase inhibitor suppressing cell proliferation, is regarded as a major melanoma susceptibility gene and the
literature has also implicated this gene in predisposition to breast cancer. Genes also known to predispose to
MM include XPD and MC1R. We studied CDKN2A/ARF, XPD and MC1R for their associations with melanoma
and breast cancer risk in Polish patients and controls. We found that CDKN2A and ARF do not contribute
significantly to either familial melanoma or malignant melanoma within the context of a cancer familial
aggregation of disease with breast cancer. However, the common variant of the CDKN2A gene A148T, previously
regarded as non-pathogenic, may predispose to malignant melanoma, early-onset breast cancer and lung
cancer. Compound carriers of common XPD variants may be at slightly increased risk of breast cancer or late-
-onset malignant melanoma. Common recurrent variants of the MC1R gene (V60L, R151C, R163Q and R160W)
may predispose to malignant melanoma. In general, the establishment of surveillance protocols proposed as
an option for carriers of common alterations in CDKN2A, XPD or MC1R variants requires additional studies.
It is possible that missense variants of genes for which truncating mutations are clearly pathogenic may also be
deleterious, but with reduced penetrance. This may be overlooked unless large numbers of patients and controls
are studied. A registry that includes 2000 consecutive breast cancer cases, 3500 early onset breast cancer
patients, 500 unselected malignant melanoma and over 700 colorectal cancer patients has been established
in the International Hereditary Cancer Centre and can contribute to these types of large association studies.
Introduction
Based on epidemiological data we can assume that
at least some malignant melanoma (MM) and breast
cancer cases can be caused by the same genetic
factors. CDKN2A, which encodes the p16 protein,
a cyclin-dependent kinase inhibitor suppressing cell
proliferation, is regarded as a major melanoma
susceptibility gene and the literature has also implicated
this gene in predisposition to breast cancer. Genes also
known to predispose to MM include XPD and MC1R.
This paper reviews a range of studies which have been
performed in Polish populations with the following
objectives:
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1. Assessment of the risk of malignancies of various
sites of origin in relatives of malignant melanoma
patients from families with strong familial cancer
aggregation.
2. Assessment of germline mutation and large deletion
analysis of the CDKN2A/ARF genes in families with
multiple melanomas and in families with an
aggregation of malignant melanoma and breast
cancer.
3. Determination of the association of CDKN2A
common variants with melanoma risk.
4. Assessment of breast cancer risk among carriers of
the common CDKN2A variants.
5. Assessment of clinical characteristics of CDKN2A-
-positive breast cancers in young women.
6. Assessment of CDKN2A common variants and
multi-organ cancer risk.
7. Assessment of XPD common variants and their
association with melanoma and breast cancer risk.
8. Assessment of MC1R common variants, CDKN2A
and their association with melanoma and breast
cancer risk.
1. Risk of malignancies of various site 
of origin in relatives of malignant
melanoma patients from families
with strong cancer familial
aggregation
(based on Debniak T, Gorski B, Cybulski C,
Jakubowska A, Kurzawski G, Kladny J, Zaluga E,
Fiedorowicz J, Debniak B, Lubinski J. Increased risk
of breast cancer in relatives of malignant melanoma
patients from families with strong cancer familial
aggregation. Eur J Cancer Prev 2003; 12: 241-245)
Population screening for familial aggregation of
malignancies performed recently by our centre for the
West Pomeranian region of Poland (population 1.5 m)
has shown that among families with strong aggregation
of tumours the most frequently diagnosed situation is
the occurrence of cancer familiar aggregations with
unknown pathogenetic background (CFA). CFA do not
match pedigree/clinical criteria of any known cancer
family syndromes and they are characterized by
occurrence of malignancies of various sites of origin
among at least three first-degree relatives. It is
important to perform analyses to clarify the background
of the CFA in order to predict their clinical behaviour,
and eventually discern how to defeat them.
One of the tumours that can occur in families with
CFA is malignant melanoma (MM). It has been shown
that constitutional BRCA1 mutations lead to familial
cancer aggregations of not only breast/ovarian cancers
but also MM [1]. In addition, it has been suggested
that in some families MM can be caused by
a predisposition to tumours of various sites [2-4].
The aim of this study was to evaluate the risk of
occurrence of malignancies of various sites in patients
with MM and their first-degree relatives from families
with CFA.
Materials and methods
The pedigree and clinical data of a series of 175
consecutive patients with MM who underwent surgery
at the Regional Oncology Hospital in Szczecin in the
period from 1997 to 2001 were reviewed in order to
select cases with histologically confirmed MM of the
skin and family history of at least two more first-degree
relatives affected by malignancies of various site of
origin (MM/CFA). Families with two or more MM cases
among first-degree relatives were considered as familial
melanomas and excluded from this study.
We identified 51 families with MM/CFA and
analyzed the tumour spectrum and age at diagnosis
of malignancies in these families, and compared it to
the general Polish population.
The study was approved by the ethics board of the
Pomeranian Medical University in Szczecin.
Results
Analysis of distribution of age at diagnosis of MM
from MM/CFA families revealed two peaks of
occurrence of melanoma cases at the ages 45-50 and
65-70 years. Thus, we identified a subgroup of 22
MM/CFA families with MM diagnosed before 55 years
with a total number of 75 malignancies among
relatives of patients with MM; and a subgroup of 29
MM/CFA families with MM diagnosed after 55 and
with a total number of 78 malignancies among
relatives of patients with MM.
Evaluation of the tumour spectrum in these families
revealed an increased proportion of breast cancers:
17.52% in the subgroup of ≤55 MM/CFA families,
12.15% in the subgroup of >55 MM/CFA families.
We also observed an increased proportion of liver
cancer, CSU (cancer site unknown) and leukaemia.
Evaluation of the mean age at diagnosis revealed
that breast cancers appear at a younger age in
comparison with the general population; mean age of
diagnosis in ≤55 MM/CFA families was 48.47 years
(Table 1).
Statistical analyses revealed a higher than expected
observed frequency of occurrence of breast cancers
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(OF 10.48% versus EF 4.54%) in MM/CFA families
≤55 MM/CFA. Related risk of occurrence of breast
cancers was especially increased in ≤55 MM/CFA
families – 3.256 (Table 2).
Summary of the results
We analysed tumour spectrum and age at diagnosis
of malignancies in 51 families with MM/CFA. Families
of patients with MM diagnosed <56 years of age
showed an increased proportion of breast cancer (OF
10.6%, EF=4.3%, mean age of diagnosis 48.5 years)
and a higher proportion of diagnosis of breast cancer
in younger age (<50 years of age, OR=3.7; RR=3.3).
2. Germline mutation and large deletion
analysis of the CDKN2A/ARF genes 
in families with multiple melanomas
and in families with an aggregation
of malignant melanoma and breast
cancer
(based on Debniak T, Gorski B, Scott RJ, Cybulski C,
Medrek K, Zowocka E, Kurzawski G, Debniak B,
Kadny J, Bielecka-Grzela S, Maleszka R, Lubinski J.
Germline mutation and large deletion analysis of the
CDKN2A and ARF genes in families with multiple
melanoma or an aggregation of malignant melanoma
and breast cancer. Int J Cancer 2004; 110: 558-562)
The results of previous studies show increased risk of
malignant melanoma (MM) in families with multiple
members affected by disease and in families characterized
by the constellation of breast cancer and MM. The reason
for that may be shared molecular base of breast cancer
and MM, like for example injury of the CDKN2A gene.
In the literature, there are some differences concerning
the frequency of constitutional mutations of the CDKN2A
gene in carriers with familiar aggregation of MM in
different populations [5-8]. In Polish familial MM (FMM),
no CDKN2A mutations have been detected to date [9].
CDKN2A shares exons 2 and 3 with another gene,
ARF, which has also been implicated in the
pathogenesis of MM [10]. Hewitt et al. described
a germline mutation of ARF in patients affected with
melanoma or breast cancer from a family with multiple
melanomas and breast cancers [11]. No studies
examining ARF in families with aggregations of MM
and breast cancer have been reported.
Methods used to screen for mutations in
CDKN2A/ARF are usually PCR-based and focus on the
detection of small sequence alterations, such as point
mutations, small deletions and insertions. Only a few
authors have searched for large CDKN2A/ARF deletions
or rearrangements [6, 12]. A novel method to analyze
Table 1. Proportion and age at diagnosis of malignancies of various site of origin in relatives of MM patients from MM/CFA families
Tumour site ≤55MM/CFA families >55MM/CFA families General population1
frequency odds mean age frequency odds mean age frequency mean age
(%) ratio at diagnosis (%) ratio at diagnosis (%) at diagnosis
breast 17 (17.52)3 2.14 48.473 13 (12.15) – 50.85 8.96 58.5
≤50 years 10 (10.3)3 3.71 – 8 (7.5)3 2.61 – 2.77 –
>50 years 7 (7.2) – – 5 (4.7) – – 6.19 –
lungs 11 (11.34) – 61.13 10 (9.34)3 – 62.23 19.15 64
colon 6 (6.19) – 65.4 9 (8.41) – 67.3 9.68 62
stomach 3 (3.09) – 61.9 6 (5.60) – 61.4 5.95 67
liver 4 (4.12) – 66.9 6 (6.54)3 – 67.7 1.77 67
skin4 3 (3.09) – 61.8 5 (4.67) – 62.1 4.47 67.6
leukaemia 3 (4.12) not done 0 not done 1.95 not done
CSU2 12 (12.38)3 not done 8 (7.47)3 not done 0.42 not done
1general Polish population (Zatoñski W, Tyczyñski J. Nowotwory w Polsce w 1999. Krajowy rejestr nowotworów, Warszawa 2001)
211 cases of ovarian, uterine or cervical cancer 6.1%, site of origin not confirmed
3p<0.05, statistically significant
4skin cancers
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large genomic alterations, multiplex ligation-dependent
probe amplification (MLPA), has been described,
enabling rapid and sensitive screening for the
identification of genomic rearrangements [13, 14].
To determine whether the CDKN2A and ARF genes
are involved in Polish FMM and aggregations of breast
cancer and MM, we applied genomic sequencing and
MLPA analysis to the molecular characterization of these
genes in DNA samples obtained from FMM patients
and from CFA families with MM and breast cancer.
Materials and methods
Patients
We examined 3 groups of families: group 1 (FMM
cases), MM probands from 16 families with at least 2
first-degree relatives affected with MM registered at
the Hereditary Cancer Centre in Szczecin; group 2 (44
cases), probands diagnosed with MM and having at
least 2 first-degree relatives, one affected with breast
cancer and the other diagnosed with either breast
cancer or a malignancy at a different site; group 3 
(22 cases), family defined by the index patient being
diagnosed with breast cancer, a first-degree relative
with melanoma and a family history of at least one
more first-degree relative affected by any malignancy.
For restriction fragment length polymorphism (RFLP)
analysis, DNA samples from 200 healthy individuals
selected at random by family doctors from the city of
Szczecin (controls) were used.
Methods
Genomic DNA was prepared from peripheral blood
leukocytes [15]. Purified PCR products were sequenced
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Table 2. Results of statistical analyses (expected and observed frequency, related risk of occurrence of malignancies of various site of origin)
in MM/CFA families
Tumour site1 Observed frequency (OF %) Expected frequency (EF %) Relative risk (RR, CI 95%)
breast2
≤55MM/CFA 142 (10.6) 5.68 (4.3) 3.256 (CI 95% 0.95–6.8)4
>55MM/CFA 132 (9.8) 11.35 (8.6) 1.145 (CI 95% 0.54–2.45)
lungs
males 17 (5.6) 12.57 (4.1) 1.352 (CI 95% 0.63–2.934)
females 4 (1.3) 2.95 (0.9) 1.358 (CI 95% 0.258–7.678)
colon
males 8 (2.6) 5.17 (1.7) 1.547 (CI 95% 0.47–5.306)
females 7 (2.2) 4.59 (1.5) 1.526 (CI 95% 0.427–5.723)
stomach
males 5 (1.6) 3.11 (1.0) 1.609 (CI 95% 0.344–8.232)
females 4 (1.3) 2.59 (0.8) 1.543 (CI 95% 0.278–9.577)
liver
males 4 (1.3) 2.24 (0.7) 1.786 (CI 95% 0.301–12.53)
females 6 (1.9) 2.50 (0.8) 2.396 (CI 95% 0.497–13.83)
skin3
males 5 (1.6) 3.41 (1.1) 1.465 (CI 95% 0.326–7.06)
females 3 (1.0) 3.88 (1.2) 0.773 (CI 95% 0.137–4.107)
1breast cancer was studied in two separate groups, the remaining tumours in one group (51 families with MM/CFA)
2women only, 3 cases of bilateral or metachronic breast cancer and 1 case of breast cancer in a man were excluded from further study
3skin cancer (basocellular or spinocellular)
4p<0.05
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directly using the Big-Dye Terminator, version 3.0
(Perkin-Elmer, Foster City, CA), sequencing reaction with
the same forward primers used previously for exonic
amplification of the CDKN2A and ARF genes.
Sequencing reaction products were separated and
analyzed on an ABI 377 DNA Sequencer (Perkin-Elmer).
For the analysis of large deletions and insertions,
the SALSA P024 CDKN2A/2B (9p21) was used. After
PCR amplification of exon 2 of CDKN2A, products
were digested with restriction enzymes BseLI and
CFR42I (both from MBI Fermentas, Vilnius, Lithuania).
The study was approved by the ethics board of the
Pomeranian Medical University in Szczecin.
Results
In group 1, there were 16 probands screened for
mutations in the CDKN2A/ARF genes. From this set of
families, there were 2 cases identified, one of which
harboured a common polymorphism (A148T) and the
other a previously unidentified missense change
(R99G).
In group 2, of 44 probands, 3 patients (6.8%) were
identified who harboured the same common
polymorphism as defined above. Only one case in
group 3 harboured the A148T change. In the control
group, there were 7 cases of 200 probands (3.5%).
There were no changes in exon 1 of the ARF gene
from any of the probands of the 3 groups. However,
the R99G change identified in CDKN2A translates to
a P144R change in the ARF expressed sequence, both
of which may result in a functional change in activity.
The rare variant identified in the FMM proband was
further analyzed in 200 individuals who had not been
reported to be affected by any malignancy. The results
revealed an absence of the R99G change in the
control population, suggesting that it is associated with
disease risk.
The presence of large deletions or insertions was
evaluated using the MLPA assay, and in none of the 3
groups were gross rearrangements of the
CDKN2A/ARF genes observed.
Summary of the results
From 16 families with strong aggregations of MM
and from 66 families with breast cancer and the other
diagnosed with either breast cancer or with strong
aggregations of malignancy at a different site, only 6
families with CDKN2A constitutional mutations were
diagnosed. Two different changes in the CDKN2A gene
were detected – A148T variant was found in 5 families,
and R99G was found in one family.
3. CDKN2A common variants and their
association with melanoma risk
(based on Debniak T, Scott RJ, Huzarski T, Byrski T,
Rozmiarek A, Debniak B, Zaluga E, Maleszka R,
Kladny J, Gorski B, Cybulski C, Gronwald J,
Kurzawski G, Lubinski J. CDKN2A common variants
and their association with melanoma risk:
a population-based study. Cancer Res 2005; 65:
835-839)
There have been 77 causative CDKN2A variants
listed in the international melanoma mutation
database, eMelanoBase. CDKN2A (OMIM 60160)
was the first to be associated with MM risk and is
regarded as the major MM susceptibility gene. The
frequency of these CDKN2A variants in the reported
populations remains undetermined; however, because
they result in an altered protein product they are
considered to account for rare familial forms of the
disease. Two common polymorphisms in the 3’
untranslated region of CDKN2A have also been
described as being associated with a modulation of
risk or disease progression. However, one study
indicates that there is no overrepresentation of the
Nt500c>g and the Nt540c>t variants in the
melanoma population [16-18]. Based on the results
of the previous paper, it was shown that in Poland,
apart from the two polymorphisms in the 3’ untranslated
region, there is one more common variant of CDKN2A
– an alanine to threonine substitution at codon 148
(A148T) – which has been estimated to be present in
approximately 3.5% of the population. Functional studies
suggest this variant is a polymorphism, which seems to
have no major affect on p16 function [19, 20]. Previous
studies have shown that the A148T polymorphism is in
linkage disequilibrium with the promoter polymorphism
P-493, which has been shown to affect gene expression
[21, 22]. Nevertheless, the A148T change has been
found to be overrepresented in melanoma kindreds (3%)
in comparison to the general population (1.8%) [18].
To establish whether the A148T, Nt500c>g, and the
Nt540c>t variants are associated with increased
melanoma risk we carried out an association study based
on genotyping 471 patients with MM and 1,210 random
control subjects from the same Polish population.
Materials and methods
Patients
The unselected case group consisted of 471 patients
with MM, comprising: a) 301 unselected patients with
MM diagnosed in northwestern Poland (Szczecin,
Hereditary Cancer in Clinical Practice 2007; 5(2)102
Gorzów Wlkp, Zielona Góra); b) 80 unselected
consecutive MM cases diagnosed in northeastern
Poland (Bia³ystok); c) 90 unselected consecutive MM
cases diagnosed in southwest Poland (Opole).
The control population consisted of 500
consecutive newborns from the clinical hospitals of
Szczecin and 710 controls selected at random from
the computerized patient lists of five family practices
in Szczecin, Bia³ystok and Opole.
Methods
The A148T variant was analyzed by RFLP PCR; PCR
products were digested with the SacII enzyme. The
Nt500c>g and the Nt540c>t variants were analyzed
by RFLP PCR; PCR products were digested with the AvaI
and HaeIII enzymes.
In cases positive in RFLP PCR, DNA samples were
sequenced to confirm the presence of the mutation.
The study was approved by the ethics board of the
Pomeranian Medical University in Szczecin.
Results
The frequency of the A148T change was assessed
in the two control populations (newborns versus adults)
and the frequencies were 2.8% and 2.95%. There were
no large differences in the frequencies of the Nt500c>g
alleles and in the frequencies of the Nt540c>t alleles
in the two control populations (Table 3). Because these
were not statistically significant (data not shown),
combined control population frequencies were used for
statistical analyses of both of these CDKN2A changes.
There was no evidence that the genotype
frequencies of the three CDKN2A variants deviated
from those expected under Hardy-Weinberg for the
control group or any of the melanoma groups.
In the melanoma population under study the
frequency of the A148T variant was significantly greater
than that observed in the control population. There
were no large differences in the frequencies of the
Nt500c>g alleles or in the frequencies of the
Nt540c>t alleles (Table 3).
To further determine the importance of the A148T
change, its frequency was assessed in patients who
were <50 years of age and compared with those >50
years. The results reveal that the frequency is greater
in the <50-year-old group compared with the >50-
-year-old group. The OR was consequently greater in
the younger age group (OR=3.5; P=0.0007)
compared with the older group (OR=2.1; P=0.0351).
The mean age of A148T carriers was 53 years and the
mean age of non-carriers was 55 years; this was not
statistically significant (P=0.632).
To further define the association of the A148T
change and its link to malignancy we examined the
occurrence of cancer of any type in first-degree
relatives of carriers compared with non-carriers.
Familial melanoma cases were excluded from this
evaluation. This analysis revealed that the carrier
population was more likely to have a relative with
malignancy compared with the non-carrier population
(57% versus 36%, respectively; P=0.03).
Because there is doubt about the functional
consequence of the A148T change, but it is in linkage
disequilibrium with a promoter polymorphism that
affects gene expression levels, 20 A148T heterozygous
carriers and 20 A148T non-carriers were studied to
determine the proportion of samples that were linked.
The results revealed that all A148T heterozygous carriers
were heterozygous A/T carriers at position P-493 and
all A148T non-carriers were A/A homozygous carriers
at position P-493.
Summary of the results
From 471 unselected patients with MM, the A148T
change was found in 7% of patients, and the Nt500c>g
and Nt540c>t variants were found in 23.6% and in
20% of patients, respectively. All estimate changes were
significantly greater in the case group than those
observed in the control population. Statistically significant
data show that the A148T (OR=2.5) variant seems to
be associated with an increased risk of developing MM,
insignificantly higher in cases diagnosed <50 years of
age (OR=3.4). There were no substantial differences in
MM diagnosed in middle age, among carriers and
non-carriers of A148T change.
4. Breast cancer risk among carriers 
of the common CDKN2A variant
(based on Debniak T, Gorski B, Huzarski T, Byrski T,
Cybulski C, Mackiewicz A, Gozdecka-Grodecka S,
Gronwald J, Kowalska E, Haus O, Grzybowska E,
Stawicka M, Swiec M, Urbanski K, Niepsuj S,
Wasko B, Gozdz S, Wandzel P, Szczylik C, Surdyka D,
Rozmiarek A, Zambrano O, Posmyk M, Narod SA,
Lubinski J. A common variant of CDKN2A (p16)
predisposes to breast cancer. J Med Genet 2005;
42: 763-765)
Candidate genes for cancers of a particular site may
be selected because they are known to predispose to
malignancies of other organs, or because they are
mutated somatically in the cells from the cancer of
interest. It is possible that missense variants of genes for
Tadeusz Dêbniak
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which truncating mutations are clearly pathogenic may
also be deleterious, but with reduced penetrance. In this
situation the association may be overlooked unless large
numbers of cancers are studied. The CDKN2A (OMIM
600160) gene is a tumour suppressor gene that is
involved in susceptibility to malignant melanoma and
has also been implicated in familial pancreatic cancer
[23]. The p16 protein is a cyclin-dependent kinase
inhibitor that suppresses cell proliferation and is
expressed in a wide range of tissues, including the breast,
and in breast cancers [24]. In a previous study
[reference], it was shown that patients with the A148T
variant have higher predisposition to MM (an alanine to
threonine substitution at codon 148) (OR=2.5;
p=0.0003). It has been suggested by Borg and
colleagues that protein truncating CDKN2A mutations
predispose women to breast cancer in the context of
a syndrome of melanoma, pancreatic cancer and breast
cancer [22]. They observed eight cases of breast cancer
in Swedish families, compared with the 2.1 expected
(p=0.002). There are few other data on this topic.
Ghiorzo et al. observed a non-significant excess of breast
cancers in seven melanoma families with CDKN2A
mutations (OR=1.9; 95% confidence interval (CI), 
0.4 to 5.6) [25]. Somatic CDKN2A mutations have not
been well studied in breast cancers, but silencing of
CDKN2A through methylation appears to be a relatively
common way of inactivating this tumour suppressor gene
in the breast [26]. Furthermore, deletion or loss of
heterozygosity at the CDKN2A locus (9p21) is relatively
common in breast cancers [27].
To establish whether this common missense variant
of CDKN2A predisposes to breast cancer we undertook
an association study on 4209 cases of breast cancer
and 3000 ethnically matched controls from Poland.
Materials and methods
During 1997-2003 in 18 treatment centres
throughout Poland family history and DNA samples
were obtained from 3318 patients with breast cancer
diagnosed before the age of 51. In a companion study,
seven of these centres also provided data on unselected
breast cancer in 891 cases diagnosed above the age
of 50 between 2000 and 2002.
The control group comprised 2000 newborn and
1000 adults from the region of Szczecin unselected for
cancer family history.
The study was approved by the ethics board of the
Pomeranian Medical University in Szczecin.
Table 3. Frequencies of CDKN2A variant alleles in cases and controls
Groups A148T OR 95% CI Nt500c>g OR 95% CI Nt540c>t OR 95% CI
newborns 0 (0%) A/A – 6 (1.2%) G/G – 4 (0.8%) T/T –
(n=500) 14 (2.8%) G/A – 88 (17.6%) G/C – 62 (12.4%) C/T –
486 (97.2%) G/G – 406 (81.2%) C/C – 434 (86.8%) C/C –
adults 0 (0%) A/A – 9 (1.3%) G/G – 3 (0.4%) T/T –
(n=710) 21 (2.95%) G/A – 143 (20.1%) G/C – 83 (11.7%) C/T –
689 (97.05%) G/G – 558 (78.6%) C/C – 625 (88%) C/C –
total 0 (0%) A/A – 15 (1.2%) G/G – 7 (0.6%) T/T –
controls 35 (2.89%) G/A – 229 (18.9%) G/C – 145 (12%) C/T –
(n=1210) 1175(97.1%)GG – 966 (79.8%) C/C – 1058(87.4%)C/C –
Allel A 1.5% – Allel G 10.7% – Allel T 6.6% –
MM* 0 (0%) A/A – 8 (1.7%) G/G 1.44 0.6–3.3 3 (0.6%) T/T 1.14 0.3–4.3
(n=471) 33 (7%) G/A 2.51 1.5–4.1 103 (21.9%) G/C 1.24 0.9–1.6 64 (13.5%) C/T 1.24 0.8–1.6
438 (93%) G/G 0.41 0.2–0.6 360 (76.4%) C/C 0.84 0.6–1.1 404 (85.7%) C/C 0.94 0.6–1.2
Allel A 3.5% 2.51 1.5–4.0 Allel G 12.6% 1.24 0.9–1.5 Allel T 7.4% 1.14 0.9–1.5
melanoma 0 (0%) A/A – 1 (0.6%) G/G 0.54 0.1–3.6 2 (1.2%) T/T 2.04 0.4–9.8
≤50 16 (9.3%) G/A 3.42 1.9–6.4 32 (18.6%) G/C 1.04 0.6–1.5 21 (12.2%) C/T 1.04 0.6–1.7
(n=172) 156 (90.7%) G/G 0.32 0.2–0.5 139 (80.8%) C/C 1.14 0.7–1.6 149 (86.6%) C/C 0.94 0.6–1.5
Allel A 4.7% 3.32 1.8–6.1 Allel G 9.9% 0.94 0.6–1.3 Allel T 7.3% 1.14 0.7–1.7
melanoma 0 (0%) A/A – 7 (2.3%) G/G 1.94 0.8–4.7 1 (0.3%) T/T 0.64 0.1–4.7
>50 17 (5.7%) G/A 2.03 1.1–3.7 71 (23.7%) G/C 1.34 1.0–1.8 43 (14.4%) C/T 1.24 0.9–1.8
(n=299) 282 (94.3%) G/G 0.53 0.3–0.9 221 (73.9%) C/C 0.74 0.5–0.9 255 (85.3%) C/C 0.84 0.6–1.2
Allel A 2.8% 2.03 1.1–3.6 Allel G 14.2% 1.44 1.0–1.8 Allel T 7.5% 1.24 0.8–1.6
*unselected malignant melanomas;
1p=0.0003, 2p=0.0002, 3p=0.0315, 4p≥0.05 – not statistically significant
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Table 4. Frequencies of CDKN2A variant alleles in breast cancer patients
Age Number tested Mutation positive Prevalence [%] Odds ratio p
≤50 years
20–30 66 8 12.10 3.8 0.0002
31–40 582 24 4.10 1.2 0.46
41–50 2670 136 5.10 1.5 0.003
total 3318 168 5.10 1.5 0.002
>50 years
51+ 891 40 4.50 1.3 0.17
Laboratory methods
The A148T variant was analyzed by PCR-RFLP. PCR
products were digested with the SacII enzyme. The
presence of the A148T change was confirmed by direct
DNA sequencing.
Results
The A148T variant was detected in 105 from 3000
cases from the control group (3.5%), 5.1% of breast
cancer patients diagnosed at age 50 or below and in
4.5% of cases diagnosed at age 51 and above (Table
4). For women diagnosed below age 51 the odds ratio
was 1.5 (p=0.002). For women diagnosed over age
50 the odds ratio was modest and non-significant
(OR=1.3; p=0.2). In the small group of patients
diagnosed with breast cancer at age 30 and under, the
prevalence of the CDKN2A variant was 12.1% and the
association was much stronger (OR=3.8; p=0.0002).
Among the 3318 women diagnosed with breast
cancer under age 50, 692 had a family history of a first-
or second-degree relative with breast cancer. For the
familial and non-familial cases there were no differences
observed in frequencies of the A148T variant.
However, the frequency of the A148T alleles was
similar in the newborn population (3.5%) and the adult
population (3.6%). The allele was equally frequent
among males (3.5%) and females (3.6%) and among
controls recruited from Szczecin (3.5%) and from
elsewhere in Poland (3.6%).
Summary of the results
We have shown that the A148T allele of the
CDKN2A gene is overrepresented in a population of
3318 unselected patients with breast cancer under age
50, and also in 891 unselected patients with breast
cancer at age 50 and above. The statistical significant
differences concern risk of breast cancer obtained only
in the group of patients with cancer diagnosed in
young age (<51 years of age, OR=1.5).
5. Clinical characteristics of CDKN2A-
-positive breast cancers in young
women from Poland
(based on Debniak T, Cybulski C, Gorski B, Huzarski
T, Byrski T, Gronwald J, Jakubowska A, Kowalska E,
Oszurek O, Narod SA, Lubinski J. CDKN2A-positive
breast cancers in young women from Poland. Breast
Cancer Res Treat 2006)
The results of previous papers suggest that the
frequent A148T change in the CDKN2A gene is
associated with higher frequency not only of MM but
also of breast cancer in young age (≤50 years of age).
To investigate the contribution of the A148T variant
to early-onset breast cancer, and to establish the
characteristic features of these cancers, we studied
3069 early-onset breast cancer cases and 3439
population controls.
Materials and methods
The case group consisted of 3267 cases with breast
cancer diagnosed under 51 years of age, unselected
in relation to family history. Among these, 198 women
carried one of the three Polish founder BRCA1
mutations (4153delA, 5328insC, C61G) and were
excluded from the present study. Information was
recorded on age at diagnosis, stage, grade and
lymph-node status, oestrogen-receptor status, multi-
centricity and bilaterality. The medical record and
pathology report were reviewed locally by the physician
associated with the study.
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The control group consisted of 2051 newborn
children from hospitals throughout Poland, and 1442
healthy adults unselected for cancer family history.
The study was approved by the ethics board of the
Pomeranian Medical University in Szczecin.
Results
An A148T variant was identified in 157 of 3069
women with breast cancer in young age (5.1%;
OR=1.4; 95% CI 1.075–1.725; P=0.012).
The characteristics of breast cancer cases in the 
157 women with CDKN2A variant were compared with
non-carriers (Table 5). The mean age of diagnosis in
women with an A148T variant was similar to that in the
non-carriers cases. The distribution of histological types
was similar in cases and controls. However, carriers of
A148T variant were more likely to be diagnosed with
intraductal cancers (DCIS) with micro-invasion than were
non-carriers (14.8% vs. 8.5%; P=0.035). Lobular
cancers were less frequent among carriers when
compared to non-carriers (16.6% vs. 1.3%), although
this difference was not significant (P=0.58).
Carriers and non-carriers were similar with respect
to tumour size; there were no significant differences
between the groups (Table 5). Carriers and non-carriers
were similar with respect to oestrogen-receptor status
(67% vs. 64%; P=0.6). Bilateral tumours were equally
common in both subgroups (3.6% vs. 3.4%; P=0.9),
multicentric cancers were also not over-represented in
any of the groups (20% vs. 18%; P=0.6).
There was no difference in cancer family history
between carriers and non-carriers of the A148T variant
– 7.5% of the carriers were from a family with two or
more first-degree relatives with breast cancer versus
9% of the non-carriers (P=0.64).
Summary of the results
The study of 3069 cases with breast cancers certifies
that carriers of the A148T variant were slightly more
likely to develop intraductal cancers (DCIS) with
micro-invasion than non-carriers (14.8% vs. 8.5%;
P=0.035). There was no difference between carriers
and non-carriers with respect to tumour size, laterality,
multicentricity, nodal status, family history or oestrogen
receptor status.
6. CDKN2A common variant 
and multi-organ cancer risk
(based on Debniak T, Scott RJ, Huzarski T, Byrski T,
Rozmiarek A, Debniak B, Gorski B, Cybulski C,
Medrek K, Mierzejewski M, Masojc B, Matyjasik J,
Zlowocka E, Teodorczyk U, Lener M, Klujszo-Gra-
bowska E, Nej-Wolosiak K, Jaworowska E,
Oszutowska D, Szymanska A, Szymanska J,
Castaneda J, van de Wetering T, Suchy J, Kurzawski
G, Oszurek O, Narod S, Lubinski J. CDKN2A
common variant and multi-organ cancer risk
– a population-based study. Int J Cancer 2006;
118: 3180-3182)
The CDKN2A variant can be found in tumours of
many organs, among others head and neck cancer,
respiratory malignancies and laryngeal cancer [28-30].
The p16 protein is expressed in a wide range of tissues,
and the full range of cancers associated with CDKN2A
mutations has yet to be determined.
Data from the literature indicate a possible
association between CDKN2A, A148T and common
MM. There is also some evidence to indicate that this
variant is associated with breast cancer at younger age.
We had also observed that the A148T heterozygous
carrier population was more likely to have a first-degree
relative with cancer of any type compared to the MM
carrier population (p=0.03).
To determine whether this A148T change may be
associated with an increased risk of malignancies at
various sites of origin, we genotyped a series of 3,583
unselected cancer cases and compared the frequency
of the change observed in this population to 3,000
controls.
Materials and methods
Cases were enrolled in the study from hospitals in
Szczecin and surrounding counties. Study subjects were
unselected for age, sex or family history. In general,
more than 75% of patients agreed to take part in the
studies. Two control groups were combined. The first
group consisted of 2,000 newborn children from ten
hospitals throughout Poland. The second control group
consisted of 1,000 unselected adults from the region
of Szczecin.
The method of examining and verifying the A148T
variant was shown previously.
The study was approved by the ethics board of the
Pomeranian Medical University in Szczecin.
Results
The A148T variant was detected in 3.5% of Polish
controls. The frequency of the alleles was similar in the
newborn population (3.4%) compared to the adult
population (P=0.83). There was no statistical difference
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in the CDKN2A allele frequencies in the newborns
recruited from the Szczecin metropolitan region
compared to other Polish cities. There was no evidence
that the genotype frequencies of the A148T variant
deviated from those expected under Hardy-Weinberg
(HWE) for the control groups (p>0.4).
The prevalence of the A148T variant was higher in
cancer cases than in controls for three of the eleven
sites studied (Table 6). The highest odds ratios were
observed among lung cancer (OR=2.0) and colon
cancer (OR=1.5) cases. For lung the excess was
statistically significant (adjusted p value after Bonferroni
correction 0.0052), and was non-significant for
colorectal cancer (unadjusted p value 0.0423,
adjusted p-value 0.5499) (Table 6).
Odds ratios were further analyzed by taking into
account the age of disease onset (≤50, >50). There
were no significant differences between early-onset
lung cancers (5/70; 7.1%) and late-onset cancers
(29/427; 6.8%). The A148T prevalence was slightly
higher in late-onset colorectal cancers (5.1%) than
in early-onset cases (4.9%) (the number of patients
with colon cancer diagnosed under age 50 was less
(n 5 122), thereby reducing the power of this result).
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Table 5. Comparison of CDKN2A-positive and CDKN2A-negative breast cancer cases
Parameters p16-positive p16-negative p
n=157 n=2912
age (mean) 44.35 44.34 0.9
age group 20–30 6/157 (3.82%) 51/2912 (1.75%) 0.11
31–40 21/157 (13.38%) 501/2912 (17.2%) 0.25
41–50 130/157 (82.80%) 2360/2912 (81.04%) 0.66
histology “low grade” 32/108 (29.63%) 637/2012 (31.66%) 0.74
“high grade” 15/108 (13.88%) 303/2012 (15.06%) 0.85
medullary 6/108 (5.55%) 112/2012 (5.57%) 0.99
lobular 18/108 (16.66%) 388/2012 (19.28) 0.58
tubulo-lobular 6/108 (5.55%) 89/2012 (4.42%) 0.75
DCIS 16/108 (14.81%) 170/2012 (8.45%) 0.04
other 15/108 (13.88%) 313/2012 (15.56%) 0.74
no data or unknown 12/108 (11.11%) 225/2012 (11.18%) 0.89
pre-operative positive 37/151 (24.5%) 675/2012 (24.5%) 0.99
chemotherapy
ER positive 61/91 (67.03%) 1085/1698 (63.9%) 0.58
tumour size <1 cm 9/99 (9.09%) 185/1767 (10.47%) 0.87
1–1.9 cm 43/99 (43.43%) 798/1767 (45.16%) 0.76
2–4.9 cm 46/99 (46.46%) 742/1767 (42%) 0.72
>5 cm 1/99 (1.01%) 42/1767 (2.38%) 0.73
nodal status positive 37/100 (37%) 752/1801 (41.75%) 0.4
multi-centricity present 18/90 (20%) 340/1898 (17.91%) 0.58
laterality present 5/138 (3.62%) 88/2573 (3.42%) 0.96
family history positive (+) 11/146 (7.5%) 240/2658 (9%) 0.64
For all comparisons, except age, bilaterality and family history, cases with pre-operative chemotherapy were excluded. Family history refers to a first-degree
relative affected with breast cancer
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Table 6. Association between A148T variants and selected types of cancer
Cases A148T OR 95% confidence interval p (adjusted)
controls 0 (0%) A/A – – –
(n=3000) 105 (3.5%) G/A – – –
2895 (96.5%) G/G – – –
Allele A frequency 1.75% – – –
bladder 0 (0%) A/A – – –
(n=223) 7 (3.1%) G/A 0.9 0.4105–1.945 0.7764 (n.s.)
216 (96.9%) G/G 1.1 0.5142–2.436 0.7764 (n.s.)
Allele A frequency 1.6% 0.9 0.4012–1.876 0.7177 (n.s.)
colon 0 (0%) A/A – – –
(n=724) 37 (5.1%) G/A 1.5 1.012–2.180 0.0423 (0.5499)
687 (94.9%) G/G 0.7 0.459–0.989 0.0423 (0.5499)
Allele A frequency 2.6% 1.5 1.008–2.151 0.0443 (0.5759)
stomach 0 (0%) A/A – – –
(n=246) 8 (3.3%) G/A 0.9 0.4461–1.925 0.8384 (n.s.)
238 (96.7%) G/G 1.1 0.5194–2.241 0.8384 (n.s.)
Allele A frequency 1.6% 0.9 0.4494–1.916 0.8398 (n.s.)
larynx 0 (0%) A/A – – –
(n=396) 17 (4.3%) G/A 1.2 0.7326–2.088 0.4255 (n.s.)
379 (95.7%) G/G 0.8 0.4790–1.365 0.4255 (n.s.)
Allele A frequency 2.1% 1.2 0.7337–2.067 0.4298 (n.s.)
ovary 0 (0%) A/A – – –
(n=340) 12 (3.5%) G/A 1.0 0.5491–1.853 0.9777 (n.s.)
328 (96.5%) G/G 1.0 0.5396–1.821 0.9777 (n.s.)
Allele A frequency 1.8% 1.0 0.5520–1.843 0.9779 (n.s.)
lung 0 (0%) A/A – – –
(n=497) 34 (6.8%) G/A 2.0 1.358–3.018 0.0004 (0.0052)
463 (93.2%) G/G 0.5 0.331–0.736 0.0004 (0.0052)
Allele A frequency 3.4% 2.0 1.342–2.945 0.0005 (0.0065)
prostate 0 (0%) A/A – – –
(n=348) 13 (3.7%) G/A 1.1 0.5946–1.925 0.8215 (n.s.)
335 (96.3%) G/G 0.9 0.5194–1.682 0.8215 (n.s.)
Allele A frequency 1.9% 1.1 0.5972–1.912 0.8231 (n.s.)
kidney 0 (0%) A/A – – –
(n=264) 6 (2.3%) G/A 0.6 0.2788–1.474 0.2915 (n.s.)
258 (97.7%) G/G 1.6 0.6782–3.586 0.2915 (n.s.)
Allele A frequency 1.1% 0.6 0.2820–1.477 0.2957 (n.s.)
thyroid 0 (0%) A/A – – –
(n=173) 3 (1.7%) G/A 0.5 0.1528–1.549 0.2129 (n.s.)
170 (98.3%) G/G 2.1 0.6454–6.545 0.2129 (n.s.)
Allele A frequency 0.9% 0.5 0.1550–1.556 0.2169 (n.s.)
nonHodgkin 0 (0%) A/A – – –
lymphoma 6 (3.7%) G/A 1.1 0.4585–2.453 0.8909 (n.s.)
(n=162) 156 (96.3%) G/G 0.9 0.4077–2.181 0.8909 (n.s.)
Allele A frequency 1.9% 1.0 0.4616–2.431 0.8918 (n.s.)
pancreas 0 (0%) A/A – – –
(n=210) 8 (3.8%) G/A 1.1 0.5246–2.273 0.8140 (n.s.)
202 (96.2%) G/G 0.9 0.4400–1.906 0.8140 (n.s.)
Allele A frequency 1.9% 1.1 0.5275–2.253 0.8156 (n.s.)
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Summary of the results
In the study of 3583 unselected patients with tumours
of many organs (other than MM and breast cancer) the
A148T variant was detected more often than among
patients with lung cancer (6.8%; OR=2.0; P=0.0004
adjusted p value after Bonferroni correction P=0.0052)
or colon cancer (5.1%; OR=1.5, P=0.0423; adjusted
p value after Bonferroni correction P=0.5499).
7. XPD common variants and their
association with melanoma 
and breast cancer risk
(based on Debniak T, Scott RJ, Huzarski T, Byrski T,
Masojc B, van de Wetering T, Serrano-Fernandez P,
Gorski B, Cybulski C, Gronwald J, Debniak B,
Maleszka R, Kladny J, Bieniek A, Nagay L, Haus O,
Grzybowska E, Wandzel P, Niepsuj S, Narod SA,
Lubinski J. XPD common variants and their
association with melanoma and breast cancer risk.
Breast Cancer Res Treat 2006; 98: 209-215)
There is continuing interest in identifying low-pene-
trance genes, which are associated with increased
susceptibility to common types of cancer. The genetic
basis of MM is complex and appears to involve multiple
genes. Individuals with the rare inherited syndrome
xeroderma pigmentosum (XP) have an approximate
1000-fold increased incidence of skin malignancies,
including melanoma [31]. There are several genes
associated with XP and these include ERCC2, ERCC3,
XP-G and XP-F [31, 32]. The XPD (ERCC2) gene product
has a dual function in basal transcription and in
nucleotide excision repair [33, 34]. In the literature there
are four reports evaluating XPD gene polymorphisms and
melanoma risk. Two of them were performed on a very
small number of cases [35, 36], whereas the other two
suggested a modest positive association of two single
nucleotide polymorphisms in exons 10 (Asp312Asn) and
23 (Lys751Gln) with either melanoma or a subset of
older onset cases of melanoma based on 219 and 176
melanoma cases, respectively [37, 38]. Recently the two
XPD variants (Asp312Asn and Lys751Gln) have also
been linked with the occurrence of breast cancer [39,
40]. Interestingly, the positive findings for Asp312Asn in
the 223 Finnish unselected breast cancer patients were
not repeated in 172 Polish familial cases [41].
To establish whether the XPD common variants
Asp312Asn and Lys751Gln are associated with
increased melanoma or breast cancer risk we
performed an association study based on genotyping
426 unselected patients with MM and 1830 consecutive
breast cancer cases compared to 1262 geographically
matched newborns and 1553 healthy adults.
Additionally we examined the prevalence of
Gly156Gly, Leu485Pro and Arg112His variants in XPD
among 421 unselected melanoma patients as it is
unknown whether these SNPs are associated with
disease risk.
Materials and methods
The first case group of 471 unselected patients with
MM consisted of: a) 301 unselected patients with MM
diagnosed in northwestern Poland (Szczecin, Gorzów
Wlkp, Zielona Góra); b) 80 unselected consecutive
MM cases diagnosed in northeastern Poland
(Bia³ystok); c) 90 unselected consecutive MM cases
diagnosed in southwest Poland (Opole).
The second case group consisted of cases of
consecutive invasive breast cancer diagnosed at 7
treatment centres throughout Poland, unselected for age
and family history (including 511 cases in the vicinity of
Szczecin). A detailed family history of cancer was
ascertained. A total of 2500 incident cases of invasive
breast cancer were identified at the 7 different centres
during the study period. Of these, 1900 women accepted
the invitation to participate in this genetic study (76%).
From the total of 1900 enrollees 70 patients could not
be genotyped because of poor quality DNA. This brought
the total number of breast cancer cases studied to 1830.
The first control group consisted of 1262
geographically matched newborn male and female
children collected in the same hospitals from where
the melanoma and breast cancer cases were collected.
The second control group consisted of 621 adults
from the region of Szczecin unselected for cancer family
history.
The third control group consisted of 421 healthy
adults matched for sex and age with the melanoma
cases and 511 healthy adults from the region of
Szczecin matched for sex and age with the breast
cancer cases collected from the city of Szczecin.
The XPD changes were analyzed by PCR-RFLP, using
the enzymes: Psp 14061 for Asp312Asn; PstI for
Lys751Gln; TfiI for Gly156Gly; HpaII for Leu485Pro;
FauI for Arg112His. DNA sequencing was undertaken
on random samples to ensure that all PCR products
represented the respective XPD alleles.
The study was approved by the ethics board of the
Pomeranian Medical University in Szczecin.
Results
There were no significant differences in the allele
frequencies of the XPD variants in all three control
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Table 7. Lys751Gln/Asp312Asn genotypes in the study and control groups
Lys751Gln Asp312Asn Melanoma Newborns OR (95% CI), p Breast cancer OR (95% CI), p
(n=423) (n=1017) (n=1713)
AA GG 115 267 1.0 (n.s.) 494 1.1 (n.s.)
(27.2%) (26.3%) (28.8%)
AA AG 28 104 0.6 (n.s.) 153 0.9 (n.s.)
(6.6%) (10.2%) (8.9%)
AA AA 2 16 0.3 (n.s.) 17 0.6 (n.s.)
(0.5%) (1.6%) (1%)
AC GG 46 107 1.0 (n.s.) 151 0.8 (n.s.)
(10.9%) (10.5%) (8.8%)
AC AG 131 334 1.0 (n.s.) 559 1.0 (n.s.)
(31%) (32.8%) (32.6%)
AC AA 28 49 1.4 (n.s.) 77 1.0 (n.s.)
(6.6%) (4.8%) (4.5%)
CC GG 7 20 0.8 (n.s.) 22 0.7 (n.s.)
(1.6%) (2%) (1.3%)
CC AG 27 51 1.3 (n.s.) 67 0.8 (n.s.)
(6.4%) (5%) (3.9%)
CC AA 39 69 1.4 (n.s.) 173 1.5 (1.2–2.1)
(9.2%) (6.8%) (10.1%) 0.004 (0.016)1
1p value calculated with the χ2 test (Bonferroni adjusted value in parantheses)
populations; also among newborns recruited from
treatment centres throughout Poland and among males
and females there were no significant differences. Since
only the newborn group consisted of cases
geographically matching the melanoma and breast
cancer patients, and as it was larger than the adult
control population, further statistical calculations were
performed only on this control group.
The expected allelotype distributions for all
polymorphisms were in Hardy–Weinberg equilibrium.
We were unable to evaluate an association between
melanoma and Arg112His and Leu485Pro since
neither of these polymorphisms were represented
among the control and subject populations used in this
study, suggesting that both changes are very rare in the
Polish population.
We found no association with the Lys751Gln and
Arg112His genotype and melanoma or breast cancer
risk. There were no statistically significant differences
in Lys751Gln and Arg112His genotype variant
prevalence between early and late-onset cases. There
were no major differences in the mean age of diagnosis
between subjects carrying the AA, AC or CC genotypes
of Lys751Gln change and the AA, AC or CC genotypes
of Lys751Gln change.
No association was observed between the
Gly156Gly genotype and melanoma risk, for either
early or late-onset melanoma. There was no major
difference in the mean age of diagnosis between the
subjects carrying AA, AC or CC genotypes.
We found an association of the Lys751Gln_
CC/Asp312Asn_AA genotype with breast cancer risk
(Table 7). The genotype was significantly over-repre-
sented among early-onset breast cancer patients
(OR=1.5, p=0.0212) and late onset cases (OR=1.5,
p=0.0169). No association between compound
heterozygous carriers of Lys751Gln and Asp312Asn
variants and melanoma risk was observed (Table 7).
The genotype Lys751Gln_CC/Asp312Asn_GG [42] is
rare in our population (1.7% in MM and 1.6% in the
control group).
Subjects carrying Lys751Gln_CC genotype and
Gly156Gly_CC genotype were associated with modest
increase of melanoma risk (OR=1.4). In a subgroup
of late-onset melanoma patients the genotype was
more tightly associated with melanoma risk with
OR=1.7, p<0.05 (Table 8).
There were no significant differences among carriers
of Asp312Asn + Gly- 156Gly genotype and the risk
of MM among early- and late-onset cases. The highest
OR (1.4) and lowest p value (0.088) reached was in
the subgroup harbouring the Asp312Asn_AA/
Gly156Gly_CC genotype.
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Table 8. Lys751Gln/Gly156Gly genotypes among melanoma and control groups
Lys751Gln Gly156Gly Melanoma (MM) Newborns 95% CI p OR
(n=424) (n=1052)
AA AA 56 (13.2%) 157 (14.9%) – n.s. 0.9
AA CA 70 (16.5%) 182 (17.3%) – n.s. 1
AA CC 19 (4.5%) 62 (5.9%) – n.s. 0.7
AC AA 7 (1.65%) 25 (2.4%) – n.s. 0.7
AC CA 130 (30.66%) 318 (30.2%) – n.s. 1
AC CC 66 (15.57%) 153 (14.6%) – n.s. 1.1
CC AA 2 (0.50%) 2 (0.2%) – n.s. 2.5
CC CA 9 (2.12%) 36 (3.4%) – n.s. 0.6
CC CC 65 (15.3%) 117 (11.12%) 1.044–2.006 0.03 (0.18) 1.4
CC CC MM≤501 117 (11.12%) – n.s. 1.1
(n=172)
21 (12.2%)
CC CC MM>501 117 (11.12%) 1.170–2.491 0.007 (0.042) 1.7
(n=250)
44 (17.6%)
p value calculated with the ÷2 test (Bonferroni adjusted value in parantheses)
1age at onset unknown in two cases of melanoma
None of the compound heterozygous genotypes
were significantly over-represented among melanoma
cases. Carriers of the Lys751Gln_CC/Asp312 Asn_GG/
Gly156Gly_CC genotype had OR=1.8 with p=0.5.
Carriers of the Lys751Gln_CC/Asp312Asn_AA/
Gly156Gly_CC genotype had OR=1.3 with p=0.3.
The high p value is due to the small numbers of carriers
with all three polymorphisms.
Haplotype frequency analyses showed a statistically
significant association in subjects carrying Lys751Gln_C/
Gly156Gly_C genotype with modest increase of MM risk
(OR=1.2; p=0.007 before Bonferroni correction;
p=0.028 after Bonferroni correction). We found an
association of the Lys751Gln_C/Asp312Asn_A genotype
with breast cancer risk. The genotype was significantly
over-represented (OR=1.2; p=0.049 before Bonferroni
correction, p=0.2 after Bonferroni correction). There was
a similar situation with Lys751Gln_C/Asp312Asn_A/
Gly156Gly_C genotype (OR=1.2; p=0.008 before
Bonferroni correction, p=0.065 after Bonferroni
correction).
Summary of the results
XPD genotype Lys751Gln_CC/Gly156Gly_CC was
detected in 15% of 471 unselected malignant
melanoma patients and 11% of controls (OR=1.4).
Significant over-representation of this genotype was
found in late-onset cases (over the age of 50, OR=1.7,
p=0.007, p=0.042 after Bonferroni correction).
XPD genotype Lys751Gln_CC/Asp312Asn_AA was
detected in 10% of 1830 unselected breast cancer
patients and 6.8% of controls. This difference was
statistically significant p=0.004 (p=0.016 after
Bonferroni correction) and OR=1.5.
8. MC1R common variants, CDKN2A
and their association with melanoma
and breast cancer risk
(based on Debniak T, Scott R, Masojc B,
Serrano-Fernandez P, Huzarski T, Byrski T, Debniak
B, Gorski B, Cybulski C, Medrek K, Kurzawski G,
van de Wetering T, Maleszka R, Kladny J, Lubinski J.
MC1R common variants, CDKN2A and their
association with melanoma and breast cancer risk.
Int J Cancer 2006; 119: 2597-2602)
One of the melanoma low-penetrance susceptibility
genes is MC1R. The MC1R gene (16q24, OMIM
155555) encodes a protein that acts as the receptor
for melanocyte-stimulating hormone (MSH). It has been
reported that some germline allelic variants of MC1R
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gene (Arg151Cys, Arg160Trp, Asp294His) are
associated with an increased risk of multiple melanomas
(MM) [43-45]. They also act as modifiers of melanoma
risk in carriers of CDKN2A mutations by increasing
disease penetrance in familial melanoma cases.
However, the majority of these reports suggesting an
association were based on the examination of
melanoma-prone families [46, 47]. The risk of MM has
only been evaluated in fair-skinned populations of
northern European [44, 48, 49] origin and in
Mediterranean populations [47, 50-53].
Recently Begg et al. pointed out that CDKN2A
mutation carriers in the general population have a much
lower risk of melanoma than that suggested by estimates
obtained from multiple-case families [54]. Similarly, the
increase of CDKN2A penetrance caused by MC1R
variants may also be lower in the general population.
To evaluate malignant melanoma risk among
carriers of common germline MC1R changes the
protein coding sequence of this gene was analysed and
the frequencies of detected DNA alterations were
evaluated among cases and controls. In order to
evaluate the phenotypic characterisation of the patient
population we included information on family
aggregation and clinical data in the analyses.
MC1R has recently been suggested to act on MM
risk via non-pigmentary mechanisms [50]. Its variant
has been reported to be associated with prostate
cancer risk. Since melanoma and breast cancer appear
to share some genetic background we also examined
the prevalence of the MC1R variants among unselected
breast cancer patients.
Materials and methods
The sequencing was performed in 40 MM patients
from families with at least two diagnosed cases among
first-degree relatives.
The association research was performed on two
case groups. The first case group consisted of 500
unselected MM patients diagnosed in few centres in
Poland. The second study population consisted of 511
prospectively ascertained cases of consecutive invasive
breast cancer diagnosed in the city of Szczecin.
The control group consisted of 800 geographically
matched newborn male and female children collected
in the same hospitals from where the melanoma and
breast cancer cases were collected: 421 healthy adults
matched for sex and age with the melanoma cases and
511 healthy women from the region of Szczecin
matched for sex and age with the breast cancer cases
collected from the city of Szczecin.
From the sequencing results 4 common variants
were identified: V60L, R151C, R163Q and R160W.
The frequency of the 4 MC1R variants was identified
by RFLP-PCR by use of enzyme: Hha I for R151C;
HindIII for R163Q; SacII for R160W. The V60L variant
was analyzed using an allele-specific PCR (ASO-PCR).
A separate DNA sample was sequenced to confirm
the presence of the mutation.
The study was approved by the ethics board of the
Pomeranian Medical University in Szczecin.
Results
Genomic sequencing of the 40 familial cases of
MM revealed 9 different SNPs. Four of them (V60L,
R151C, R163Q and R160W) were regarded as
common variants (they were detected in at least 10%
of familial cases) and used in further analyses.
There were no significant differences in the allele
frequencies of the MC1R variants in the 2 control
populations. Since only the newborn group consisted
of cases geographically matching the melanoma and
breast cancer patients, and as it was larger than the
adult control population, further statistical calculations
were performed only on this control group.
Haplotype analysis in melanoma patient population
We found a statistically significant association of
the R151C variant (p=0.000008; OR 5 2.9, 95% CI
1.82–4.67), the V60L variant (p=0.007; OR 5 1.78;
95% CI 1.2–2.64), the R160C variant (p=0.006; OR
5 1.76; 95% CI 1.75–2.62) and the R163Q variant
(p=0.015; OR 5 2.1 95% CI 1.1–3.97) with melano-
ma risk.
The presence of any of those 4 common MC1R
variants was significantly higher among patients than
in the control population (p=0.0000004).
Additionally the association between carriers of the
common A148T variant of CDKN2A and the 4 MC1R
polymorphisms was evaluated. None of the compound
heterozygotes were significantly over-represented
among any of the melanoma cases (data not shown).
Nevertheless, the highest OR (4.2) was observed in
patients harbouring the A148T variant in CDKN2A and
the R151C variant in MC1R.
Although the average age at diagnosis of carriers
was always 1–2 years lower than among non-carriers,
for each of the 4 common MC1R variants separately,
none of these differences was significant. However,
there was a statistically significant difference of almost
6 years (t-test, one-tailed; p=0.039) when comparing
the age at diagnosis of compound carriers (average
48.4 years) with non-carriers (average 54.2 years).
There was a significantly higher frequency of
melanoma occurrence among first-degree relatives of
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Table 9. Occurrence of melanoma and breast cancer among first-degree relatives of MM probands
Feature R160W p 95% CI OR
first-degree relatives carriers (+) non-carriers (–)
affected with n=85 n=373
melanoma3 4 (4.7%)1 17 (4.5%)2 n.s. – –
breast cancer4 4 (4.7%) 25 (6.7%) n.s. – –
R151C
carriers (+) non-carriers (–)
n=74 n=401
melanoma 7 (9.5%) 11 (2.7%) 0.0097 1.276–9.061 3.4
breast cancer 5 (6.7%) 25 (6.2%) n.s. – –
V60L
carriers (+) non-carriers (–)
n=78 n=354
melanoma 5 (6.4%) 10 (2.8%) n.s. – 2.4
breast cancer 5 (6.4%) 24 (6.7%) n.s. – –
R163Q
carriers (+) non-carriers (–)
n=30 n=354
melanoma 1 (3.3%) 13 (3.6%) n.s – –
breast cancer 2 (5%) 17 (4.8%) n.s – –
any of four none of four
variants positive variants positive
carriers (+) non-carriers (–)
n=245 n=149
melanoma 17 (6.9%) 3 (2.0%) 0.03 1.05–12.60 3.6
breast cancer 16 (6.5%) 8 (5.4%) n.s – –
1percentage of carriers with at least one affected first-degree relative
2percentage of probands without MC1R variants but with at least one affected first-degree relative
3number of melanoma cases among first-degree relatives
4number of breast cancer cases among first-degree relatives
carriers of any of the MC1R variants in comparison to
non-carriers (p=0.03; OR=3.6). Analogously there
was a slight increase in the prevalence of all MC1R
variants among melanoma probands with a first- or
second-degree relative affected by melanoma (7/40;
17.5%) when compared to unselected cases (73/474;
15.4%).
There were no significant differences in frequency
of breast cancer in first-degree relatives and in patients
without changes in the MC1R gene (Table 9).
The analysis of the clinical data revealed
a significant increase of melanoma occurrence on
non-exposed skin areas among carriers of any of the
MC1R variants (p 5 0.0014; OR 5 2.2). We also
observed an almost 5-fold increase of multiplicity of
melanoma among carriers of any of the MC1R
variants. There was no association between those
variants and tumour type (Table 10).
Haplotype analysis in breast cancer patient population
We found no association with the MC1R variants
and breast cancer risk. There were no statistically
significant differences in the prevalence of the MC1R
Hereditary Cancer in Clinical Practice 2007; 5(2) 113
Some Molecular and Clinical Aspects of Genetic Predisposition to Malignant Melanoma and Tumours of Various Site of Origin
variants between early and late onset cases. None of
the compound heterozygotes (2 or more MC1R
changes, also MCIR alterations with the A148T
CDKN2A variant) were significantly over-represented
among cases (data not shown).
Summary of the results
Among 500 unselected MM the four variants of
MC1R gene were found more frequently in the control
group: R151C (15.4% MM; OR=2.9; p=0.000 008),
V60L (18.2% MM; OR=1.8; p=0.007), R160C
(19.3%; OR=1.8; p=0.006) and R163Q (7.8%;
OR=2.1; p=0.015). In carriers of the mentioned
changes MM appears with higher frequency on
non-exposed skin areas (p=0.0014). Mentioned
melanoma appears with higher frequency among
first-degree relatives of carriers of mentioned changes
of the MC1R gene (p=0.0097). We certify a statistically
significant difference of almost 6 years in comparing
the age at diagnosis of compound carriers of variants
of the MC1R gene.
Table 10. Clinical data comparison of carriers versus non-carriers of MC1R variants
Feature Carriers (+) Non-carriers (–) p (95% CI) OR
R160W
multiplicity1 3/852 (3.5%) 6/3743 (1.6%) n.s. 2.2
localization-skin4 2.45 1.3 n.s. 1.8
tumour type6 607/208/109/410 58/20/9/5 n.s.
R151C
multiplicity 3/73 (4.1%) 7/402 (1.7%) n.s. 2.4
localization in skin 2.2 1.4 n.s. 1.5
tumour type 57/21/9/5 54/19/10/6 n.s.
V60L
multiplicity 2/78 (2.6%) 6/355 (1.7%) n.s. 1.5
localization in skin 2.0 1.4 n.s. 1.4
tumour type 58/22/11/4 57/20/11/3 n.s.
R163Q
multiplicity 1/30 (3.3%) 8/355 (2.2%) n.s. 1.5
localization in skin 1.9 1.5 n.s. 1.3
tumour type 60/19/10/5 58/18/9/5 n.s.
any of four none of four variants
variants positive positive
multiplicity 8/254 (3.1%) 1/149 (0.7%) n.s. 4.8
localization in skin 2.2 1.0 0.0014 (1.35–3.63) 2.2
tumour type 61/21/8/5 60/20/9/4 n.s.
1synchronic or metachronic tumours
2number of multiple melanoma cases/total number of MC1R variant carriers
3number of multiple melanoma cases/total number of patients without MC1R variants
4regions of exposed skin: head, nape, neck, forearms, palms, shanks, feet; regions of unexposed skin: trunk, thighs, arms, buttocks
5unexposed to exposed skin ratio – number of melanomas in unexposed skin divided by number of melanomas in exposed skin
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The highest risk of affected MM was observed
among carriers of A148T and R151C variant (OR=4.2);
there were no statistically significant data for subgroups
of carriers with two or more changes in the MC1R gene
or carriers with A148T and MC1R genes.
Evaluation of 511 unselected breast cancer patients
revealed no association with the MC1R variants and
breast cancer risk.
General conclusions
The outcomes of our various studies lead us to the
following conclusions.
Systematic breast surveillance beginning at the age
35–40 years should be considered as an option for
women from families with strong cancer familial
aggregation of malignancies of various site of origin
and for women with malignant melanoma diagnosed
under 56 years of life. The outcome of such
surveillance would need to be monitored in a research
setting to determine its clinical value.
In the Polish population CDKN2A and ARF do not
contribute significantly to either familial melanoma or
malignant melanoma within the context of a cancer
familial aggregation of disease with breast cancer.
Therefore, in this population, there appears to be no
strong indication for CDKN2A and ARF testing in these
familial cases.
The common variant of the CDKN2A gene A148T,
previously regarded as non-pathogenic, may predispose
to malignant melanoma, early-onset breast cancer and
lung cancer. A148T is significantly over-represented in
women with early-onset breast cancer and may
predispose to intraductal cancers (DCIS) with
micro-invasion. It seems thus justified to propose
mammography, in a research setting, beginning at the
age of 35 as an option for carriers of the A148T variant.
Compound carriers of common XPD variants may
be at slightly increased risk of breast cancer or
late-onset malignant melanoma.
Common recurrent variants of the MC1R gene
(V60L, R151C, R163Q and R160W) may predispose
to malignant melanoma.
In general, the establishment of surveillance
protocols proposed as an option for carriers of
common alterations in CDKN2A, XPD or MC1R
variants requires additional studies.
All the above-mentioned variants are low-penetrant
changes characterized by a negative cancer family
history. Thus, the use of DNA tests is the only way to
find carriers of these changes with increased risk of
tumour development. Identification of low penetrance
DNA alterations may be very important if the
simultaneous presence of such alternations and/or
combinations with external risk factors in a carrier
would add up to a clinically significant high risk of
tumour development. It will be a big challenge to study
the possible cumulative effects on cancer risk of the
many different combinations of low-penetrance
mutations. Studies of this kind will need very large
cohorts to establish reliable risk estimates.
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